-
PROVIDERS
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
LIFE SCIENCES
Introducing the Immune Profile Score
Explore the science behind the IPS test, a prognostic biomarker for patients on ICI therapy
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
09/20/2022
Patient recruitment at the speed of science
Learn how Sermonix Pharmaceuticals partnered with Tempus and its TIME network of clinical sites to accelerate patient recruitment for a phase 2 study.
Authors
Sibel Blau, MD
President and CEO, Quality Cancer Care Alliance Network
Medical Director, Northwest Medical Specialties
Matthew Cooney, MD
Vice President, Therapeutic Development, Tempus
President and CEO, Quality Cancer Care Alliance Network
Medical Director, Northwest Medical Specialties
Matthew Cooney, MD
Vice President, Therapeutic Development, Tempus
-
11/13/2024Navigating complex cell therapy trials with Compass CRO
Learn how Compass provided CRO services for a biotech’s first-in-human, dose-escalation, and expansion basket trial targeting advanced solid tumors.
Read more -
10/17/2024Precision pathways: Insights & strategies to navigate regulatory requirements for oncology diagnostics
Watch as we explore the evolving regulatory landscape of diagnostics in oncology. Gain insights into new regulatory requirements, submission pathways, and emerging trends. Learn from industry experts about strategic approaches to FDA requirements to help inform your diagnostic development and precision medicine pipelines.
Watch replay -
10/11/2024Revolutionizing drug screening with Tempus AI’s advanced imaging capabilities
Learn how Tempus AI's noninvasive imaging techniques allow for the continuous study of the same organoids across various assays, preserving their viability for longitudinal analysis and multiplexed testing.
Read more